Summary Slide.png (107.16 kB)

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

figure

posted on 2020-11-05, 10:30 authored by Aixin Shi, Panpan Xie, Lasse Lykke Nielsen, Trine Vang Skjøth, Xuemei He, Sine Pfeiffer Haugaard

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s12325-020-01548-y

Usage metrics

Read the peer-reviewed publication

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

Advances in Therapy

Keywords

Diabetes Glucagon-like peptide-1 receptor agonist Pharmacokinetics Randomised controlled trial Semaglutide Steady state exposure

Licence

CC BY-NC 4.0

Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports